HVEM / BTLA / CD160 Y PD-L1/PD1 como dianas inmunoterapéuticas en el tratamiento de tumores hematopoyéticos

Artículo

1. Assesment of Hypoderma infestation in a wild population of Cervus elaphus from mountains Atlantic ecosystems in southwestern Europe (Spain) 2024

   Veterinary Research Communications

2. Genetic deletion of HVEM in a leukemia B cell line promotes a preferential increase of PD-1- stem cell-like T cells over PD-1+ T cells curbing tumor progression 2023

   Frontiers in Immunology

3. The impact of CD160 deficiency on alloreactive CD8 T cell responses and allograft rejection 2022

   Translational Research

4. Differential Engraftment of Parental A20 PD-L1 WT and PD-L1 KO Leukemia Cells in Semiallogeneic Recipients in the Context of PD-L1/PD-1 Interaction and NK Cell-Mediated Hybrid Resistance 2022

   Frontiers in Immunology

5. Critical role of PD-L1 expression on non-tumor cells rather than on tumor cells for effective anti-PD-L1 immunotherapy in a transplantable mouse hematopoietic tumor model 2020

   Cancer Immunology, Immunotherapy